"Nov. 12, 2012 -- iPads and other tablets with backlit screens may allow millions of people with "low vision" to read faster and easier, a new study suggests.
Low vision is an umbrella term for people who still have trouble reading, wa"...
QUIXIN® (levofloxacin ophthalmic solution 0.5%) solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
|AEROBIC GRAM-POSITIVE MICROORGANISMS||AEROBIC GRAM-NEGATIVE MICROORGANISMS|
|Corynebacterium species*||Acinetobacter Iwoffii*|
|Staphylococcus aureus||Haemophilus influenzae|
|Staphylococcus epidermidis||Serratia marcescens*|
|Streptococcus (Groups C/F)|
|Streptococcus (Group G)|
|Viridans group streptococci|
|*Efficacy for this organism was studied in fewer than 10 infections.|
DOSAGE AND ADMINISTRATION
Days 1 and 2
Instill one to two drops in the affected eye(s) every 2 hours while awake, up to 8 times per day.
Days 3 through 7
Instill one to two drops in the affected eye(s) every 4 hours while awake, up to 4 times per day.
QUIXIN® (levofloxacin ophthalmic solution) 0.5% is supplied in a white, low density polyethylene bottle with a controlled dropper tip and a tan, high density polyethylene cap in the following size: 5 mL fill in 5 cc container - NDC 68669-135-05
Store at 15° – 25°C (59° – 77°F).
Manufactured by: Santen Oy, P. O. Box 33, FIN-33721 Tampere, Finland. Licensed from: Daiichi Sankyo Co., Ltd., Tokyo, Japan. Marketed by: VISTAKON® Pharmaceuticals, LLC Jacksonville, FL 32256 USA. April 2006 Version. FDA revision date: 4/11/2005
Last reviewed on RxList: 12/18/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Quixin Information
Quixin - User Reviews
Quixin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Get breaking medical news.